Literature DB >> 30505838

A Simple Noninvasive Score Predicts Disease Activity and Deep Remission in Ulcerative Colitis.

Amr Shaaban Hanafy1, Mohamed Hesham Monir1, Hany Abdel Malak2, Mohamed Desoky Aiad3.   

Abstract

BACKGROUND: There is a need to use noninvasive markers in refining the management of ulcerative colitis to reduce the number of unnecessary colonoscopies, which facilitates the follow-up of activity and the response to treatment. AIM: Postulation of a sensitive, specific, simple and noninvasive score to monitor disease activity in ulcerative colitis.
METHODS: A case-control study was conducted: 168 patients with ulcerative colitis, 40 healthy individuals, and 60 patients for validation. Patients were divided into new diagnosis (n = 50), clinical remission (n = 60), and relapse (n = 58). The main outcome measures if the score correlates with clinical, endoscopic and histopathological characteristics and if it correlates with deep remission.
RESULTS: A scoring system was established composed of lactoferrin at a cutoff of 148.5 μg/mL, neutrophil lymphocyte ratio at a cutoff of 2.35, erythrocyte sedimentation rate at the first hour at a cutoff of 29.5 mm/h, C-reactive protein at a cutoff of 3.85 mg/L, mean platelet volume at a cutoff of 8.8 fL, fecal white blood cells at a cutoff of 9 cells/HPF, and fecal red blood cells at a cutoff of 6 cells/HPF. A score ≥5 can detect 94% of cases of UC as determined by the receiver operating characteristic curve with a sensitivity of 94% and a specificity 100%, AUC 0.92, SE 0.05, p = 0.001, 95% CI 0.82-1.1. In the validation group, it identified severely affected patients with a sensitivity of 95% and a specificity of 85.7%.
CONCLUSIONS: This easily applied and reproducible noninvasive activity score showed high performance in predicting disease activity and deep remission in ulcerative colitis.

Entities:  

Keywords:  Deep remission; Disease activity; Noninvasive score; Prediction; Ulcerative colitis

Year:  2018        PMID: 30505838      PMCID: PMC6266024          DOI: 10.1159/000490795

Source DB:  PubMed          Journal:  Inflamm Intest Dis        ISSN: 2296-9365


  24 in total

Review 1.  Inflammatory bowel disease in pregnancy.

Authors:  Sunanda Kane
Journal:  Gastroenterol Clin North Am       Date:  2003-03       Impact factor: 3.806

2.  Cortisone in ulcerative colitis; final report on a therapeutic trial.

Authors:  S C TRUELOVE; L J WITTS
Journal:  Br Med J       Date:  1955-10-29

3.  Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.

Authors:  Jost Langhorst; Sigrid Elsenbruch; Julia Koelzer; Andreas Rueffer; Andreas Michalsen; Gustav J Dobos
Journal:  Am J Gastroenterol       Date:  2007-10-04       Impact factor: 10.864

4.  Hospitalized prevalence and 5-year mortality for IBD: record linkage study.

Authors:  Lori A Button; Stephen E Roberts; Michael J Goldacre; Ashley Akbari; Sarah E Rodgers; John G Williams
Journal:  World J Gastroenterol       Date:  2010-01-28       Impact factor: 5.742

5.  Assessment of neutrophil-lymphocyte ratio in ulcerative colitis: a promising marker in predicting disease severity.

Authors:  Serkan Torun; Bilge Demirel Tunc; Burak Suvak; Hakan Yildiz; Adnan Tas; Abdurrahim Sayilir; Yasemin Ozin Ozderin; Yavuz Beyazit; Ertugrul Kayacetin
Journal:  Clin Res Hepatol Gastroenterol       Date:  2012-07-27       Impact factor: 2.947

6.  Neutrophil-lymphocyte ratio as a predictor of disease severity in ulcerative colitis.

Authors:  Mehmet Celikbilek; Serkan Dogan; Omer Ozbakır; Gökmen Zararsız; Hamit Kücük; Sebnem Gürsoy; Alper Yurci; Kadri Güven; Mehmet Yücesoy
Journal:  J Clin Lab Anal       Date:  2013-01-04       Impact factor: 2.352

7.  Faecal Lactoferrin, Calprotectin, PMN-elastase, CRP, and White Blood Cell Count as Indicators for Mucosal Healing and Clinical Course of Disease in Patients with Mild to Moderate Ulcerative Colitis: Post Hoc Analysis of a Prospective Clinical Trial.

Authors:  Jost Langhorst; James Boone; Romy Lauche; Andreas Rueffer; Gustav Dobos
Journal:  J Crohns Colitis       Date:  2016-02-13       Impact factor: 9.071

8.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.

Authors:  K W Schroeder; W J Tremaine; D M Ilstrup
Journal:  N Engl J Med       Date:  1987-12-24       Impact factor: 91.245

9.  Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease.

Authors:  M C Dubinsky; J J Ofman; M Urman; S R Targan; E G Seidman
Journal:  Am J Gastroenterol       Date:  2001-03       Impact factor: 10.864

10.  Fecal lactoferrin, a marker of intestinal inflammation in children with inflammatory bowel disease.

Authors:  Anna Borkowska; Anna Liberek; Grażyna Łuczak; Agnieszka Jankowska; Katarzyna Plata-Nazar; Maria Korzon; Barbara Kamińska
Journal:  Acta Biochim Pol       Date:  2015-09-04       Impact factor: 2.149

View more
  1 in total

1.  Application of the neutrophil to lymphocyte ratio in the diagnosis and activity determination of ulcerative colitis: A meta-analysis and systematic review.

Authors:  Lushun Ma; Xinyuan Pang; Guofeng Ji; Xinrui Ma; Jie Li; Yuan Chang; Chong Ma
Journal:  Medicine (Baltimore)       Date:  2021-10-22       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.